Radiotherapy vs. No Radiotherapy after breast conserving surgery (BCS) for in-situ breast cancer. Luc Vakaet.

Slides:



Advertisements
Similar presentations
Updates on Breast Diseases: What clinicians need to know from pathologists Preah Bat Norodom Sihanouk Hopsital, 22 April 2009 Monirath Hav, MD, Ph.D. fellow.
Advertisements

The Present and Future of Genomics in DCIS
Breast Cancer. Introduction Most common female cancer Accounts for 32% of all female cancer 211,300 new cases yearly and rising 40,000 deaths yearly.
DCIS – Are we cutting it? Dr Alex Lemaigre With thanks to:
History of the randomized evidence on early breast cancer overall survival: Radiation vs no radiation after mastectomy L. Vakaet 2006.
ANDREW NG PRINCE OF WALES HOSPITAL Role of primary chemoradiation in esophageal carcinoma.
Potential interactions and timing of radiotherapy and hormonal therapy
San Antonio Breast Cancer Symposium 2007 Highlights – Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford.
Ductal Carcinoma In Situ: Where Are We Now?
Joint Hospital Surgical Grand Round Accelerated partial breast irradiation: where should we go? Dr Ma Kwok Kuen Queen Mary Hospital.
SON Breast Cancer Update: Current Controversies Oct 18, 2014 Who should we radiate and why? Lorna Weir Radiation Oncologist BC Cancer Agency, Vancouver.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Sentinel Lymph Node Dissection (SND)
Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.
Radiotherapy in Carcinoma of the Breast Patrick S Swift, MD Director, Radiation Oncology Alta Bates Comprehensive Cancer Center Berkeley, CA.
Margins: less is just as good
Hot topics in breast radiotherapy Mark Beresford.
Meta-analysis of trials of radiotherapy in DCIS Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
Breast Cancer Screening Beyond 70 Years Old Henry Kwok Breast Imaging Fellow BreastScreen Aotearoa Counties Manukau.
Non-Invasive Breast Cancer: Non-Invasive Breast Cancer: Ductal Carcinoma In-situ Vassi Gardikas, MD, FACS Ellen Malek, CTR 2011 Oncology Services Annual.
Ductal Carcinoma in situ
Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist.
Breast Cancer - the Evidence for Current Management
Elshami M.Elamin, MD Medical Oncologist Central Care Cancer Center Wichita, KS, USA
Breast conservation in Locally advanced breast cancer Department of Endocrine Surgery College of Medicine Amrita Institute of Medical Sciences Kochi, Kerala.
GÜNTHER GRUBER Institut für Radio-Onkologie ksa.ch RADIOTHERAPY IN BREAST CANCER (PART 1: CONSERVATION)
Dilemma in management of DCIS
Ductal Carcinoma In Situ (DCIS)
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
Breast Cancer: The Profile Ma. Belen E. Tamayo,M.D. Medical Oncologist Makati Medical Center The Medical City.
Management of DCIS KWH Experience Dr. Carmen Ho.
Controversies in Radiation Therapy for Breast Cancer?
Radiation Breast Oncology Highlights of SABC 2006 Alison Bevan, MD PhD UCSF Radiation Oncology January, 2007.
Ductal Carcinoma In Situ Shahla Masood, M.D. Professor of Pathology University of Florida College of Medicine - Jacksonville Chief of Pathology and Laboratory.
Post-mastectomy radiotherapy Sabine Balmer Majno Radiation Oncology Geneva University Hospital SRO Tutorial 20/09/2006.
Evidence Based For invasive breast cancer BCT is Tumor excision, axillary node dissection, whole breast radiation Modified mastectomy is total mastectomy.
LESLEY STREET ADVISOR: DR. HADLEY DCIS: The Treatment Debate.
Katie Ludwig FY1.   50, 285 New cases of breast cancer  11, 716 deaths  78% - 10 year survival rates  27% preventable cases  Source:
18th Annual Perspectives in Breast Cancer
Targeted Intraoperative Radiotherapy versus Whole Breast Radiotherapy for Breast Cancer (TARGIT-A Trial): An International, Prospective, Randomised, Non-Inferiority.
Best first ? The ATAC completed treatment analysis Professor Jack Cuzick Wolfson Institute of Preventive Medicine, London, UK.
1789 patients, 1982 – 1989, premenopausal, node + or Tumor > 5cm, M0 Total mastectomy, level I + II (partly) + CMF +/- 50Gy/25fx (electrons + photons)
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
CJ Allegra, G Yothers, MJ O’Connell, MS Roh, RW Beart, NJ Petrelli, S Lopa, S Sharif, and N Wolmark Neoadjuvant Therapy For Rectal Cancer: Mature Results.
Adjuvant chemotherapy in Rectal Cancer?. What is the evidence for adjuvant chemotherapy? Do patients achieving a pathological complete response need chemotherapy?
“Big Data, Better Treatment”: The work of the Early Breast Cancer Trialists’ Collaborative Group Rory Collins BHF Professor of Medicine & Epidemiology.
Hormone treatment combined with radiotherapy
Radiotherapy Protocols Bristol protocol version 12.
Anastrozole (‘Arimidex’): a new standard of care?
‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial: Completed Treatment Analysis.
Preliminary Results of the MRC CR07 / NCIC CO16 Randomized Trial Short course pre-op vs selective post-op chemo-RT for rectal cancer Local Recurrence after.
Inferring the Effects of Cancer Treatment: Divergent Results from the Early Breast Cancer Trialists’ Collaborative Group Meta-analyses of Randomized Trials.
Refining Radiotherapy for Early Breast Cancer: The Challenges. David Dodwell Radiotherapy in Practice Sheffield Hallam University October 2010.
Annals of Oncology 24: 2206–2223, 2013 R3 조영학
ABSTRACT Purpose This retrospective review was conducted to determine if delay in the start of radiotherapy after conservative breast surgery had any detrimental.
Department of Clinical Radiotherapy, Royal Marsden Hospital, Sutton, Surrey SM2 5PT, UK R4 한재준 1.
The impact of age on outcome in early-stage breast cancer 방사선종양학과 R2. 최진현.
KONTROVERSEN IN DER RADIOTHERAPIE DES MAMMAKARZINOMS
Surgical Management of the Breast in Breast Cancer
Intellectual property of the EBCTCG trialists.
Personalisiertes Vorgehen im Bereich des Lymphabflusses
Intraoperative radiotherapy for early breast cancer
What is the optimal pre-op therapy for esophagus and GE junction cancers?
Alan P. Venook, MD University of California, SF
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient.
THE LANCET Oncology Volume 19, No. 1, p27–39, January 2018
Presentation transcript:

Radiotherapy vs. No Radiotherapy after breast conserving surgery (BCS) for in-situ breast cancer. Luc Vakaet

Clash of the titans Bernard FisherMelvin Silverstein

EBCTCG: RT vs no RT for DCIS Study NameInclusion criteriaEntry# ptsPrescriptionMargins clear? NSABP B-17Lumpectomy Gy to breastNo EORTC 10853Local Excision; Age < Gy to breastNo Swedish DCIS Study Quadrantectomy Gy to breastNo Stockholm 8Breast-Conserving Surgery Gy to breastNo UK DCIS TrialScreen-Detected; Complete Local Excision; Gy to breastYes Total4092 EBCTCG Preliminary results. Not for publication or citation

Results: Isolated local recurrence

Preliminary results. Not for publication or citation EBCTCG Preliminary results. Not for publication or citation

RT prevents only clinically unimportant non-invasive recurrences? NSABP B-17 JCO 1998

Can we select patients that would not or very little benefit from RT Does DCIS size matter? => Only for DCIS > 5 cm Does patient age matter? => Unnecessary for patients older than 70 Does margin width matter? => Margins more than 1 cm is OK Does differentiation matter? => Only for patients with Grade 3

Margin width < 1 cm Silverstein et al. NEJM 1999 What about the Van Nuys Prognostic Index (VNPI)?

Does DCIS size matter? EBCTCG Preliminary results. Not for publication or citation

Does age matter? NSABP B-17 JCO 1998

UKNZL DCIS Study: Always re-excision when margins are positive Lancet 2003

EORTC 10 yrs FU of local recurrence JCO 2006

Summary of the scientific evidence 10.6 % (p < ) absolute gain in any recurrence by year % relative reduction of the risk of recurrence. no difference in breast cancer mortality or any death by year 10. The gain in recurrence is statistically significant in any subgroup analysed. There are no prospectively verified prognostic indices for local recurrence. We cannot (yet) define a subgroup of patients with sufficiently low risk to exclude radiation after BCS.